Background and Objectives: Accurately estimating fetal weight is critical for optimal obstetric management. This study aimed to evaluate the efficacy of using fetal liver length, measured via ultrasonography, to predict estimated fetal weight (EFWG). The specific objectives were to assess fetal weight using fetal liver length, establish predictive mathematical formulas, correlate liver length with EFWG, and quantify the strength of the association between fetal liver parameters and fetal weight. Methods: A cross-sectional study was conducted on a sample of 173 pregnant women with confirmed normal pregnancies at Ultrasound Department of Al-Auda Medical Center in Hafr Al-Batin, KSA; Pregnancies with suspected congenital abnormalities were excluded. Sonographic evaluations were performed using a real-time grayscale scanner (Mindray and Fujifilm) equipped with a 3.5 MHz curvilinear array transducer. Data collection involved measuring fetal liver length, and the data were analyzed using bivariate correlation and multiple linear regression methods. Results: The proposed simple linear regression analysis revealed that fetal liver length demonstrated a strong positive linear correlation with estimated fetal weight (R = 0.766). The coefficient of determination (R2 = 0.587) confirms that approximately 58.7 % of the total variance in fetal weight can be directly explained by liver length alone. The adjusted R2 (0.585) further substantiates the stability and reliability of the model. The analysis of variance yielded an F-statistic of 243.082 (p < 0.001), verifying that the regression model is highly significant and that the relationship is robust rather than a result of random chance. The derived unstandardized model provides a direct mathematical formula for clinical application: EFW G = -1637.782 + 492.151 X (Liver Length). The unstandardized coefficient for liver length (B = 492.151, t = 15.591, p < 0.001) confirms its critical role in assessing fetal growth parameters. Overall, these findings validate fetal liver length as a dependable, highly accurate metric for clinical estimation of fetal weight in routine obstetrical evaluations. This equation specifies that for every 1 cm increase in fetal liver length, the estimated fetal weight increases by approximately 492.15 g. Conclusion: The findings demonstrate that fetal liver length is a robust and statistically significant predictor of estimated fetal weight, offering a reliable, alternative parameter for comprehensive fetal growth assessment in clinical practice.

This work is about finding probable new anti-Ebola drugs. A formula [1] is used for that purpose- (Log A/Log B) =64.5/C-H-N-O. Where, C-H-N-O is molecular weight of the Ebola virus antigens. This formula was used to identify probable new anti-HIV drugs [2] and the cause of dementia [3]. Use of the formula [1] -(Log A/Log B) =64.5/C-H-N-O, to identify the constitution of probable anti Ebola drugs. “Log A is Logarithm of molecular weight (elemental atomic weight multiplied by number of molecules of that element) of individual element(s) of drug. Log B is Logarithm of molecular weight of similar element(s) of Deoxy Ribose Nucleic Acid (DNA). C-H-N-O is basic effector. 64.5 Kda is the molecular weight of a complex effector molecule-Haemoglobin. Atomic weight of the element x number of molecules of the same molecule = Molecular weight of that element in either DNA or Drug” [1].

Objective: To evaluate the association and discriminatory performance of diffusion MRI-derived apparent diffusion coefficient (ADC) values for ¹⁸F-FDOPA PET-defined metabolic activity in newly diagnosed glioma. Methods: This was a retrospective study of 87 treatment-naïve adults, who were initially evaluated for newly diagnosed or radiologically suspected glioma at Baghdad Teaching Hospital, Medical City, Baghdad from January 2026 to July 2026. Pretreatment diffusion MRI and ¹⁸F-FDOPA PET/CT results were evaluated. PET activity was determined a priori as TBRmax ≥1.60 as an approximated operational application of PET RANO 1.0. The mean ADC was compared across PET groups, associated with SUVmax and TBRmax and assessed by ROC analysis. WHO grade analyses were done in 80 individuals with histological confirmation. Results: Forty-six tumors were PET-active and 41 were PET-inactive. Mean ADC was lower in PET-active tumors (1.04 ± 0.24 vs 1.16 ± 0.23 ×10⁻³ mm²/s; p=0.029), whereas SUVmax was higher (3.73 ± 0.98 vs 2.06 ± 0.45; p<0.001). ADC correlated inversely with TBRmax (Spearman rho=−0.32; p=0.003) and SUVmax (rho=−0.29; p=0.006). The AUC was 0.62 (95% CI, 0.50–0.74). At ADC ≤1.20 ×10⁻³ mm²/s, sensitivity was 84.8%, specificity 41.5%, and accuracy 64.4%. Conclusion: ADC was moderately inversely correlated with 18F-FDOPA uptake but was poor in discriminative ability alone. The lower bound of the AUC confidence interval was near chance performance. The cutoff from this cohort is experimental and should not be used for guiding clinical choices without external confirmation.